China Amorphous PDLLA Filler Uniform Degradation Injectable Wrinkle Fillers for sale

Amorphous PDLLA Filler Uniform Degradation Injectable Wrinkle Fillers

Name: Amorphous PDLLA Filler Uniform Degradation Injectable Wrinkle Fillers
Brand: Guangdong Fitakh Pharmaceutical Biotechnology Co., Ltd.

Price Negotiable

Price: 40USD

MOQ: 1

Delivery Time: 3-5 DAYS

Brand: FITAKH

Product Description

Amorphous PDLLA Filler with Uniform Degradation and Natural Collagen Regeneration for Anti-Aging

PDLLA Filler Products Description:

Technical Principle: Medical-grade PDLLA is an amorphous random copolymer polymerized by DL-lactic acid monomers, featuring a disordered molecular chain structure without regular crystal lattices. Different from crystalline PLLA, its non-crystalline structure delivers softer texture and more uniform tissue compatibility after subcutaneous injection. The core working mechanism relies on mild and steady ester bond hydrolysis in physiological environments. Polymer long chains are gradually decomposed into natural lactic acid, which is further metabolized into carbon dioxide and water with zero toxic residues. During the slow degradation process, PDLLA continuously activates dermal fibroblasts, promotes autologous collagen hyperplasia and regeneration, and realizes the dual effect of physical filling support and biological skin rejuvenation.
Production Process: PDLLA adopts strict medical-grade sterile polymerization and deep purification procedures. High-purity DL-lactic acid raw materials are screened and refined to remove impurities, moisture and invalid monomers. Precision ring-opening polymerization is carried out under constant temperature and pressure with controllable catalytic conditions to form uniform high-molecular-weight PDLLA polymers. Multiple devolatilization and ultra-filtration purification processes are applied to thoroughly eliminate residual catalysts and micro-impurities. The whole synthesis, granulation and packaging process is completed in Class 100 dust-free sterile workshops, ensuring ultra-low sensitization, stable molecular weight distribution and consistent batch quality for clinical aesthetic injection.
Core Technical Parameters: The core component is medical-grade Poly-DL-Lactic Acid (PDLLA) with ultra-high purity of ≥99.5%. It adopts amorphous random copolymer structure, with customizable molecular weight ranging from 50000 to 100000 Da. The in-vivo degradation cycle is stable at 12 to 18 months. All products comply with ISO 10993 biocompatibility safety standards. The final degradation products are natural lactic acid, carbon dioxide and water, achieving complete metabolism and residue-free safety performance for long-term clinical aesthetic applications.